TB support in Swaziland

Eswatini

Eswatini (formerly Swaziland) has one of the world’s highest rates of HIV, with nearly one in three adults living with the disease. However, around 80 per cent of people with TB in Eswatini are HIV positive.

Estimates suggest that HIV incidence rates in Eswatini have fallen in recent years, as significant progress has been made in improving the number of people receiving antiretroviral (ARV) treatment.

We continue to help more HIV patients access ARV treatment through the ’test and start’ strategy. A team has been piloting ‘test and start’ in the Nhlangano project; after HIV testing, ARV treatment was offered to more than 1,700 people after a positive HIV diagnosis to immediately start treatment.

We now treat patients with extensively drug-resistant TB (XDR-TB), and those developing severe side effects, using the promising new drugs bedaquiline and delamanid in combination with repurposed drugs.

MSF teams are currently responding to the coronavirus COVID-19 pandemic in Eswatini.

In 2019
 
Video Observed Therapy (VOT) training for MDR-TB patients in Matsanjeni health centre
Coronavirus COVID-19 pandemic

Eswatini: Responding to COVID-19 in a country already fighting a dual HIV/TB epidemic

Interview 8 May 2020
 
Malawi - Advanced HIV
HIV/AIDS

AIDS death toll stagnating due to lack of testing at community level

Press Release 1 Dec 2019
 
Malawi - Advanced HIV
HIV/AIDS

MSF report "No time to lose" examines the fight against AIDS in 15 countries

Report 27 Nov 2019
 
TB support in Swaziland
Eswatini

MSF hands over its Manzini project, while continuing activities in Shiselweni

Statement 25 Jun 2018
 
TB support in Swaziland
Eswatini

"A long and gruelling seven years and now it is over"

Voices from the Field 29 Jun 2017
 
Sign language training and TB support in Swaziland
Eswatini

For patients with XDR-TB, treatment is a gruelling journey with severe side effects

Voices from the Field 27 Feb 2017